The Promise and Pitfalls of Digital Medication

Publication Title
U.S. Pharmacist
Publication/Creation Date
July 18 2019
Tina Caliendo (creator)
Olga Hilas (creator)
Media Type
Journal Article
Persuasive Intent

In November 2017, the FDA approved the Abilify MyCite system. This drug-device combination product consists of aripiprazole tablets with an ingestible event marker (IEM) sensor and a wearable sensor patch that detects the signal from the IEM sensor after ingestion, which in turn transmits data to a smartphone application. Patients can use a Web-based portal to allow monitoring by healthcare professionals and caregivers for the purpose of tracking drug ingestion and adherence. Although this new digital technology provides a means to potentially enhance adherence and yield better patient health outcomes, ethical issues may arise for both patients and providers. US Pharm. 2019;44(7):22-24.
HCI Platform
Relation to Body
Related Body Part
Digestive Tract

Date archived
July 4 2020
Last edited
July 5 2021
How to cite this entry
Tina Caliendo, Olga Hilas. (July 18 2019). "The Promise and Pitfalls of Digital Medication". U.S. Pharmacist. Jobson Medical Information LLC. Fabric of Digital Life.